Stratified treatment for pediatric rhabdomyosarcoma based on risk factors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of the SYSUCC-RMS treatment regimen for children diagnosed with rhabdomyosarcoma (RMS). It will assess the impact of combining chemotherapy and radiotherapy on survival rates across different risk categories: low, medium, high, and extremely high risk. The study will include pediatric patients aged 0 to 18 years who are receiving treatment for the first time and will monitor their outcomes based on their specific risk factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 0 years \< age \< 18 years old, regardless of gender;
2. Tumor patients diagnosed by histopathology or bone marrow cytology;
3. Patients are treated for the first time;
4. ECoG score ≤ 2;
5. The expected survival time is more than 8 months;
6. Patient's parent or guardian signs informed consent.

Exclusion Criteria:

1. Combined with immunodeficiency disease
2. Second tumor

Where it's running

• Suying Lu
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Suying Lu
• Email: lusy@sysucc.org.cn
• Phone: +020-87342460

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Pucotenlimab with standard chemotherapy for pediatric rhabdomyosarcoma

  This study is testing if adding a new drug called Pucotenlimab to standard chemotherapy can help children and teens with a type of cancer called rhabdomyosarcoma.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06456892

• FaceSay: a computer program to help kids recognize facial expressions and improve social interactions

  A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07923370

• Access to Innovative Cancer Treatments for Children and Young People in Belgium

  This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT07727694

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

  This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.

  Recruiting Resonance, Inc. · Yerevan and 5 other locations · NCT07632014

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.